359 related articles for article (PubMed ID: 33798554)
1. Hsp70 chaperone blocks α-synuclein oligomer formation via a novel engagement mechanism.
Tao J; Berthet A; Citron YR; Tsiolaki PL; Stanley R; Gestwicki JE; Agard DA; McConlogue L
J Biol Chem; 2021; 296():100613. PubMed ID: 33798554
[TBL] [Abstract][Full Text] [Related]
2. Hsp27 reduces glycation-induced toxicity and aggregation of alpha-synuclein.
Vicente Miranda H; Chegão A; Oliveira MS; Fernandes Gomes B; Enguita FJ; Outeiro TF
FASEB J; 2020 May; 34(5):6718-6728. PubMed ID: 32259355
[TBL] [Abstract][Full Text] [Related]
3. Endosulfine-alpha inhibits membrane-induced α-synuclein aggregation and protects against α-synuclein neurotoxicity.
Ysselstein D; Dehay B; Costantino IM; McCabe GP; Frosch MP; George JM; Bezard E; Rochet JC
Acta Neuropathol Commun; 2017 Jan; 5(1):3. PubMed ID: 28069058
[TBL] [Abstract][Full Text] [Related]
4. The effects of the novel A53E alpha-synuclein mutation on its oligomerization and aggregation.
Lázaro DF; Dias MC; Carija A; Navarro S; Madaleno CS; Tenreiro S; Ventura S; Outeiro TF
Acta Neuropathol Commun; 2016 Dec; 4(1):128. PubMed ID: 27938414
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of an aggregation-prone variant of alpha-synuclein used to model synucleinopathies.
Masaracchia C; König A; Valiente-Gabioud AA; Peralta P; Favretto F; Strohäker T; Lázaro DF; Zweckstetter M; Fernandez CO; Outeiro TF
Biochim Biophys Acta Proteins Proteom; 2020 Jan; 1868(1):140298. PubMed ID: 31676453
[TBL] [Abstract][Full Text] [Related]
6. Assessing the subcellular dynamics of alpha-synuclein using photoactivation microscopy.
Gonçalves S; Outeiro TF
Mol Neurobiol; 2013 Jun; 47(3):1081-92. PubMed ID: 23389286
[TBL] [Abstract][Full Text] [Related]
7. Alpha-synuclein and chaperones in dementia with Lewy bodies.
Cantuti-Castelvetri I; Klucken J; Ingelsson M; Ramasamy K; McLean PJ; Frosch MP; Hyman BT; Standaert DG
J Neuropathol Exp Neurol; 2005 Dec; 64(12):1058-66. PubMed ID: 16319716
[TBL] [Abstract][Full Text] [Related]
8. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D
Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the α-Synuclein Virus Vector-Based Parkinson's Disease Mouse Model by Decreasing α-Synuclein Oligomeric Species in Mouse Brain.
Svarcbahs R; Julku UH; Myöhänen TT
J Neurosci; 2016 Dec; 36(49):12485-12497. PubMed ID: 27927963
[TBL] [Abstract][Full Text] [Related]
10. Chemical induction of Hsp70 reduces α-synuclein aggregation in neuroglioma cells.
Kilpatrick K; Novoa JA; Hancock T; Guerriero CJ; Wipf P; Brodsky JL; Segatori L
ACS Chem Biol; 2013 Jul; 8(7):1460-8. PubMed ID: 23594135
[TBL] [Abstract][Full Text] [Related]
11. Molecular dissection of amyloid disaggregation by human HSP70.
Wentink AS; Nillegoda NB; Feufel J; Ubartaitė G; Schneider CP; De Los Rios P; Hennig J; Barducci A; Bukau B
Nature; 2020 Nov; 587(7834):483-488. PubMed ID: 33177717
[TBL] [Abstract][Full Text] [Related]
12. Prominent astrocytic alpha-synuclein pathology with unique post-translational modification signatures unveiled across Lewy body disorders.
Altay MF; Liu AKL; Holton JL; Parkkinen L; Lashuel HA
Acta Neuropathol Commun; 2022 Nov; 10(1):163. PubMed ID: 36371251
[TBL] [Abstract][Full Text] [Related]
13. Do Lewy bodies contain alpha-synuclein fibrils? and Does it matter? A brief history and critical analysis of recent reports.
Lashuel HA
Neurobiol Dis; 2020 Jul; 141():104876. PubMed ID: 32339655
[TBL] [Abstract][Full Text] [Related]
14. Chaperone proteostasis in Parkinson's disease: stabilization of the Hsp70/alpha-synuclein complex by Hip.
Roodveldt C; Bertoncini CW; Andersson A; van der Goot AT; Hsu ST; Fernández-Montesinos R; de Jong J; van Ham TJ; Nollen EA; Pozo D; Christodoulou J; Dobson CM
EMBO J; 2009 Dec; 28(23):3758-70. PubMed ID: 19875982
[TBL] [Abstract][Full Text] [Related]
15. Posttranslational modification and mutation of histidine 50 trigger alpha synuclein aggregation and toxicity.
Xiang W; Menges S; Schlachetzki JC; Meixner H; Hoffmann AC; Schlötzer-Schrehardt U; Becker CM; Winkler J; Klucken J
Mol Neurodegener; 2015 Mar; 10():8. PubMed ID: 25886189
[TBL] [Abstract][Full Text] [Related]
16. Two C-terminal sequence variations determine differential neurotoxicity between human and mouse α-synuclein.
Landeck N; Strathearn KE; Ysselstein D; Buck K; Dutta S; Banerjee S; Lv Z; Hulleman JD; Hindupur J; Lin LK; Padalkar S; Stanciu LA; Lyubchenko YL; Kirik D; Rochet JC
Mol Neurodegener; 2020 Sep; 15(1):49. PubMed ID: 32900375
[TBL] [Abstract][Full Text] [Related]
17. DJ-1 interactions with α-synuclein attenuate aggregation and cellular toxicity in models of Parkinson's disease.
Zondler L; Miller-Fleming L; Repici M; Gonçalves S; Tenreiro S; Rosado-Ramos R; Betzer C; Straatman KR; Jensen PH; Giorgini F; Outeiro TF
Cell Death Dis; 2014 Jul; 5(7):e1350. PubMed ID: 25058424
[TBL] [Abstract][Full Text] [Related]
18. Detection of novel intracellular alpha-synuclein oligomeric species by fluorescence lifetime imaging.
Klucken J; Outeiro TF; Nguyen P; McLean PJ; Hyman BT
FASEB J; 2006 Oct; 20(12):2050-7. PubMed ID: 17012257
[TBL] [Abstract][Full Text] [Related]
19. Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation.
Lázaro DF; Rodrigues EF; Langohr R; Shahpasandzadeh H; Ribeiro T; Guerreiro P; Gerhardt E; Kröhnert K; Klucken J; Pereira MD; Popova B; Kruse N; Mollenhauer B; Rizzoli SO; Braus GH; Danzer KM; Outeiro TF
PLoS Genet; 2014 Nov; 10(11):e1004741. PubMed ID: 25393002
[TBL] [Abstract][Full Text] [Related]
20. A single amino acid substitution differentiates Hsp70-dependent effects on alpha-synuclein degradation and toxicity.
Klucken J; Shin Y; Hyman BT; McLean PJ
Biochem Biophys Res Commun; 2004 Dec; 325(1):367-73. PubMed ID: 15522241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
